Overactive Bladder (OAB)



Clinical and Urodynamic Predictors for Sacral Neuromodulation Outcomes in Overactive Bladder


Condition:   Overactive Bladder
Intervention:   Device: Sacral Neuromodulator "InterStim"
Sponsors:   Assiut University;   University Hospitals Cleveland Medical Center
Active, not recruiting - verified May 2017


Study of ONO-8577 in Patients With Overactive Bladder


Condition:   Overactive Bladder
Interventions:   Drug: ONO-8577;   Drug: solifenacin succinate + mirabegron;   Drug: Placebo
Sponsor:   Ono Pharmaceutical Co. Ltd
Not yet recruiting - verified March 2017


Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder


Condition:   Overactive Bladder
Interventions:   Other: electroacupncture;   Drug: Mirabegron 50 MG [Myrbetriq]
Sponsor:   University Hospitals Cleveland Medical Center
Not yet recruiting - verified March 2017


Overactive Bladder Posterior Tibial Implantable MIcro STimulator - 1


Condition:   Overactive Bladder
Intervention:   Device: The RENOVA tibial nerve stimulation system
Sponsors:   Rainbow Medical;   BlueWind Medical
Withdrawn - verified May 2017


Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial


Condition:   Overactive Bladder
Intervention:   Device: StimRouter
Sponsor:   Bioness Inc
Recruiting - verified May 2017


A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)


Condition:   Overactive Bladder
Interventions:   Drug: Botulinum Toxin Type A for Injection;   Drug: Placebo
Sponsor:   Lanzhou Institute of Biological Products Co., Ltd
Enrolling by invitation - verified September 2016


Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System


Condition:   Overactive Bladder
Intervention:   Device: Axonics Sacral Neuromodulation (SNM) System
Sponsor:   Axonics Modulation Technologies, Inc.
Recruiting - verified March 2017


Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.


Condition:   Overactive Bladder
Intervention:   Drug: Fesoterodine
Sponsors:   Stéphane Bolduc;   Pfizer
Recruiting - verified November 2016


The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides


Condition:   Overactive Bladder
Intervention:   Drug: conjugated estrogen
Sponsor:   Loyola University
Active, not recruiting - verified January 2017


Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children


Condition:   Overactive Bladder
Interventions:   Drug: Fesoterodine;   Drug: Oxybutynin XL
Sponsors:   Stéphane Bolduc;   Pfizer
Enrolling by invitation - verified December 2016


Foot Neuromodulation for Overactive Bladder in Children


Condition:   Overactive Bladder
Intervention:   Device: Transcutaneous Electrical Nerve Stimulator (TENS)
Sponsor:   Children's Hospital of Pittsburgh
Enrolling by invitation - verified August 2016


Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)


Condition:   Overactive Bladder (OAB)
Interventions:   Drug: Mirabegron;   Drug: Placebo
Sponsor:   Astellas Pharma Global Development, Inc.
Recruiting - verified March 2017


Educating Patients on Management of Overactive Bladder: Written Versus Verbal Instructions


Condition:   Overactive Bladder
Intervention:   Other: Written List
Sponsor:   St. Michael's Hospital, Toronto
Recruiting - verified October 2016


A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)


Condition:   Overactive Bladder (OAB)
Interventions:   Drug: Mirabegron;   Drug: Tolterodine ER
Sponsor:   Astellas Pharma Global Development, Inc.
Completed - verified October 2016


Does Bladder Training Improve the Efficacy of Nerve Stimulation in Women With Refractory Overactive Bladders


Condition:   Overactive Bladder
Interventions:   Behavioral: Bladder Training (BT);   Device: Percutaneous Tibial Nerve stimulation
Sponsor:   Plymouth Hospitals NHS Trust
Recruiting - verified June 2016


Oxybutynin and Omega-3 for OAB (Overactive Bladder)


Condition:   Overactive Bladder
Interventions:   Drug: Omega 3 Fatty Acid;   Drug: Placebo
Sponsor:   TriHealth Inc.
Terminated - verified March 2017


Foot/Hand Neuromodulation for Overactive Bladder (OAB)


Condition:   Overactive Bladder
Intervention:   Device: Foot stimulation
Sponsor:   University of Pittsburgh
Enrolling by invitation - verified May 2017


OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder


Condition:   Overactive Bladder
Interventions:   Biological: onabotulinumtoxinA;   Drug: Normal saline
Sponsor:   Allergan
Completed - verified May 2017


Utilization of the BIOWAVE Device to Treat Overactive Bladder


Condition:   Overactive Bladder
Intervention:   Device: Biowave Treatment
Sponsor:   Kenneth Peters, MD
Completed - verified October 2016


Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome


Condition:   Overactive Bladder
Interventions:   Drug: Detrusitol 4mg QD and Oxybutynin ER 5mg QD;   Drug: Detrusitol 4mg QD
Sponsor:   Buddhist Tzu Chi General Hospital
Completed - verified March 2017


Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.


Condition:   Overactive Bladder
Intervention:  
Sponsors:   Michael Chancellor, MD;   William Beaumont Hospitals
Completed - verified January 2017


Over Active Bladder Patients Having Sling Surgery


Condition:   Overactive Bladder
Interventions:   Drug: Solifenacin;   Other: Placebo
Sponsors:   Cleveland Clinic Florida;   Astellas Pharma US, Inc.
Completed - verified April 2017


Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?


Condition:   Overactive Bladder
Intervention:  
Sponsor:   University of Rochester
Completed - verified April 2017


Detrol LA vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms


Condition:   Overactive Bladder
Interventions:   Drug: Tolterodine LA;   Drug: Estrace Vaginal Cream
Sponsors:   University of Alabama at Birmingham;   Pfizer
Completed - verified April 2017


Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder


Condition:   Overactive Bladder
Interventions:   Drug: Darifenacin;   Drug: Placebo
Sponsors:   Novartis;   Procter and Gamble
Completed - verified May 2017

Refine Your Search Advanced Search